scholarly journals NCCN Task Force Report: Oral Chemotherapy

2008 ◽  
Vol 6 (S3) ◽  
pp. S-1-S-14 ◽  
Author(s):  
Saul N. Weingart ◽  
Elizabeth Brown ◽  
Peter B. Bach ◽  
Kirby Eng ◽  
Shirley A. Johnson ◽  
...  
Keyword(s):  
Task Force ◽  
Chemotherapeutic Agents ◽  
Oral Chemotherapy ◽  
Sense Of Control ◽  
Office Visits ◽  
Task Force Report ◽  
Significant Safety ◽  
Roles And Responsibilities ◽  
The Impact ◽  
Traditional Roles

Oral chemotherapy is emerging as a new option for well-selected patients who can manage potentially complex oral regimens and self-monitor for potential complications. If a choice between oral and parenteral therapy is available, patients may opt for oral chemotherapy because it is more convenient to administer, allows them to avoid multiple office visits, and gives them a sense of control over their own cancer care. Whether these potential advantages are maintained in regimens that combine oral and parenteral drugs is less clear. The use of oral chemotherapeutic agents profoundly affects all aspects of oncology, including creating significant safety and adherence issues, shifting some traditional roles and responsibilities of oncologists, nurses, and pharmacists to patients and caregivers. The financing of chemotherapy is also affected. To address these issues, the NCCN convened a multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy. (JNCCN 2008;6[Suppl 3]:S1–S14)

Development and validation of men's sexualizing behaviors of women scale

2017 ◽  
Author(s):  
◽  
Dominique A. Malebranche
Keyword(s):  
Factor Analysis ◽  
Task Force ◽  
High Reliability ◽  
Future Research ◽  
Sexual Objectification ◽  
Adult Males ◽  
Gender Based Violence ◽  
Task Force Report ◽  
Traditional Masculinity ◽  
The Impact

[ACCESS RESTRICTED TO THE UNIVERSITY OF MISSOURI AT AUTHOR'S REQUEST.] Sexualization has been posited to be a part of a larger process of socialization with negative implications (APA, 2010; Ward, 2016). Recent reviews of gender-based violence and exploitation have focused on important elements that highlight the impact of the pervasive experiences of sexual objectification and sexual commodification on women and girls, but relatively limited literature has explored domains of men's sexualizing behaviors. Using the theoretical domains outlined in the APA Task Force Report on the Sexualization of Girls (APA, 2010), the present study developed and validated a measure of men's sexualizing behaviors toward women (MSBWS) on a sample of 308 adult males (ages 18-34). Using exploratory factor analysis, results indicated three-factors that defined the MSBWS: Covert, Commodified, and Overt Sexualization. Analyses also revealed the MSBWS to have high reliability for the overall scale as well as the three subscales. Evidence for construct validity was revealed in significant correlations with all criterion variables (e.g., attitudes of sexual objectification, traditional masculinity and sexual aggression) and suggest broad implications that men's sexualizing behaviors is a measurable construct. Future research may further validate the MSBWS using confirmatory factor analysis on independent samples and examine relevant variables of the possible harm of sexualizing behaviors.

scholarly journals NCCN Task Force Report: Specialty Pharmacy

2010 ◽  
Vol 8 (Suppl_4) ◽  
pp. S-1-S-12 ◽  
Author(s):  
Rowena N. Schwartz ◽  
Kirby J. Eng ◽  
Deborah A. Frieze ◽  
Tracy K. Gosselin ◽  
Niesha Griffith ◽  
...  
Keyword(s):  
Economies Of Scale ◽  
Task Force ◽  
Distribution Channel ◽  
Pharmacy Practice ◽  
Health Care Team ◽  
Drug Expenditure ◽  
Task Force Report ◽  
Specialty Pharmacy ◽  
Oncology Practice ◽  
The Impact

The use of specialty pharmacies is expanding in oncology pharmacy practice. Specialty pharmacies provide a channel for distributing drugs that, from the payor perspective, creates economies of scale and streamlines the delivery of expensive drugs. Proposed goals of specialty pharmacy include optimization of pharmaceutical care outcomes through ensuring appropriate medication use and maximizing adherence, and optimization of economic outcomes through avoiding unwarranted drug expenditure. In oncology practice, specialty pharmacies have become a distribution channel for various agents. The use of a specialty pharmacy, and the addition of the pharmacist from the specialty pharmacy to the health care team, may not only provide benefits for care but also present challenges in oncology practice. The NCCN Specialty Pharmacy Task Force met to identify and examine the impact of specialty pharmacy practice on the care of people with cancer, and to provide recommendations regarding issues discussed. This report provides recommendations within the following categories: education and training of specialty pharmacy practitioners who care for individuals with cancer, coordination of care, and patient safety. Areas for further evaluation are also identified.

scholarly journals The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report

2009 ◽  
Vol 27 (2) ◽  
pp. 298-303 ◽  
Author(s):  
Tom Monclair ◽  
Garrett M. Brodeur ◽  
Peter F. Ambros ◽  
Hervé J. Brisse ◽  
Giovanni Cecchetto ◽  
...  
Keyword(s):  
Classification System ◽  
Task Force ◽  
Risk Group ◽  
Staging System ◽  
Risk Classification ◽  
Clinical Staging ◽  
Task Force Report ◽  
Clinical Criteria ◽  
Stage 1 ◽  
The Impact

Purpose The International Neuroblastoma Risk Group (INRG) classification system was developed to establish a consensus approach for pretreatment risk stratification. Because the International Neuroblastoma Staging System (INSS) is a postsurgical staging system, a new clinical staging system was required for the INRG pretreatment risk classification system. Methods To stage patients before any treatment, the INRG Task Force, consisting of neuroblastoma experts from Australia/New Zealand, China, Europe, Japan, and North America, developed a new INRG staging system (INRGSS) based on clinical criteria and image-defined risk factors (IDRFs). To investigate the impact of IDRFs on outcome, survival analyses were performed on 661 European patients with INSS stages 1, 2, or 3 disease for whom IDRFs were known. Results In the INGRSS, locoregional tumors are staged L1 or L2 based on the absence or presence of one or more of 20 IDRFs, respectively. Metastatic tumors are defined as stage M, except for stage MS, in which metastases are confined to the skin, liver, and/or bone marrow in children younger than 18 months of age. Within the 661-patient cohort, IDRFs were present (ie, stage L2) in 21% of patients with stage 1, 45% of patients with stage 2, and 94% of patients with stage 3 disease. Patients with INRGSS stage L2 disease had significantly lower 5-year event-free survival than those with INRGSS stage L1 disease (78% ± 4% v 90% ± 3%; P = .0010). Conclusion Use of the new staging (INRGSS) and risk classification (INRG) of neuroblastoma will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world.

Sign in / Sign up

Export Citation Format

Share Document